This is the authors' abstract. We don't add key points for this paper.
Gemcitabine is a pyrimidine analog with a similar chemical structure and mechanism of action, as cytarabine. It has been shown to be a highly active agent for non-small cell lung cancer, pancreatic cancer, urothelial cancer, breast cancer and ovarian cancer. Gemcitabine is relatively well tolerated and myelosuppression is the dose-limiting toxicity. Pulmonary toxicity with gemcitabine is relatively uncommon, but a well recognized entity, associated with significant morbidity and mortality. A high index of suspicion, early diagnosis and timely intervention with oxygen supplementation, steroids, and diuretics is necessary to manage patients with this complication.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: